Tirzepatide and Retatrutide—New Frontiers in Metabolic Therapy
While tirzepatide is already FDA-approved, retatrutide is still in clinical trials and creating buzz as a potential next-gen treatment.
Triple vs Dual Hormone Action
- Tirzepatide: Dual GIP/GLP-1 receptor agonist.
- Retatrutide: Triple agonist—GIP, GLP-1, and glucagon receptors.
In early studies, retatrutide has shown even greater weight loss than tirzepatide, potentially exceeding 24% body weight reduction in some participants. However, more research is needed to confirm long-term safety and effectiveness.
Tirzepatide remains the most advanced option available now, while retatrutide could be a game-changer in the near future.
Disclaimer: This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before starting or adjusting any medication.
